Emerging echinocandin-resistant Candida albicans and glabrata in Switzerland

46Citations
Citations of this article
44Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Echinocandins represent the first-line therapy of candidemia. Echinocandin resistance among Candida spp. is mainly due to acquired FKS mutations. In this study, we report the emergence of FKS-mutant Candida albicans/glabrata in Switzerland and provide the microbiological and clinical characteristics of 9 candidemic episodes. All patients were previously exposed to echinocandins (median 26 days; range 15–77). Five patients received initial echinocandin therapy with persistent candidemia in 4 of them. Overall mortality was 33%.

References Powered by Scopus

This article is free to access.

This article is free to access.

360Citations
402Readers

This article is free to access.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Coste, A. T., Kritikos, A., Li, J., Khanna, N., Goldenberger, D., Garzoni, C., … Lamoth, F. (2020). Emerging echinocandin-resistant Candida albicans and glabrata in Switzerland. Infection, 48(5), 761–766. https://doi.org/10.1007/s15010-020-01475-8

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 13

59%

Researcher 6

27%

Professor / Associate Prof. 2

9%

Lecturer / Post doc 1

5%

Readers' Discipline

Tooltip

Medicine and Dentistry 7

37%

Immunology and Microbiology 6

32%

Biochemistry, Genetics and Molecular Bi... 4

21%

Neuroscience 2

11%

Save time finding and organizing research with Mendeley

Sign up for free